Shay Capital’s Crescent Biopharma CBIO Stock Holding History

Shay Capital’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,568	Closed	-$74.9K	–	370
2025 Q1	$74.9K	Buy	+3,568	New	+$95.5K	0.01%	279

Other funds holding CBIO

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Shay Capital's CBIO Position: Q2 2025 in Review

Shay Capital sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 3,568 shares — an estimated $74.9K sold.

Shay Capital first reported a position in CBIO in Q1 2025 and held it in 1 quarter. The position peaked at $74.9K in Q1 2025. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

Shay Capital reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
Shay Capital sold 3,568 Crescent Biopharma shares in Q2 2025, an estimated $74.9K.
Shay Capital first reported a position in Crescent Biopharma in Q1 2025 and held it in 1 quarter.
Shay Capital's Crescent Biopharma position peaked at $74.9K in Q1 2025.
30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on Shay Capital's 13F filing for Q2 2025, filed 14 Aug 2025.